

GAIL

Steady progress

GAIL's adjusted EBITDA/PAT of Rs24/15bn declined 6/20% QoQ even as YoY performance looks outsized due to a lower base (EBITDA/PAT up 3.9/6x YoY). Earnings missed estimates of Rs31.8bn EBITDA and Rs21.7bn PAT primarily due to higher than estimated impact of the planned maintenance shutdown of the petchem segment in Q1. Other than petchem, most other segments delivered a strong Q1, with gas trading and the LPG + liquid hydrocarbon (LPG/LHC) segment delivering strong growth. Gas transmission saw some impact of the second wave of Covid, but Q2 onwards, most operational metrics look decidedly better. We remain positive on gas volumes, petchem and LPG margins, and trading prospects over the next 18 months. BUY, with a TP of Rs195. Current valuations are at 7.8x FY23E EPS and 6x EV/EBITDA.

Operational metrics – petchem shutdown drags down metrics

Gas transmission EBIT was Rs9.15bn (+28% YoY, -4% QoQ; below estimate of Rs9.85bn), with volumes of 108mmSCMD (down 2mmSCMD QoQ; estimate 110mmSCMD). Petchem EBIT was Rs1.4bn (-190% YoY, -77% QoQ; CenE Rs4.3bn), driven by 25% YoY and 41% QoQ dip in volumes to 138kt (estimate 193kt) due to the planned shutdown being longer than estimated. LPG+LHC EBIT of Rs6.3bn rose 2.3x YoY and 34% QoQ, above our estimate of Rs6.2bn. Gas trading was expectedly the biggest standout, with EBIT of Rs3.8bn, the highest in five quarters, driven by strong Asian LNG prices vs US HH. Overall, GAIL has guided 7-8% yearly accretion to transmission volumes and flattish petchem and LPG volumes for FY22-23, with stronger trading margins.

Multiple levers for earnings growth over the next few years

We remain optimistic about the prospects of this business over the next 12 months due to (i) sharply higher spot LNG prices, which have created a favorable price balance for the US trading cargo and should persist in the next 12-18 months, (ii) higher domestic gas supply, higher LNG and demand growth coupled with expansion of transmission capacity, (iii) better pricing environment for both the petchem and LPG segments, which augurs well for the margin profile over the next two years, and (iv) an aggressive capex program in transmission capacity and petchem, and expansion of RW energy profile, which will create a new segment of growth for GAIL in the longer term.

On track for a strong earnings trajectory over the next 2-3 years

We see FY21-23E EBITDA/EPS CAGR at a healthy 34/28%, despite the muted Q1FY22 performance, helped by the factors mentioned above. We have upgraded FY22/23E EPS estimates by 1.3/3.7% to factor better trading margins, slightly higher transmission volumes, and better LPG/LHC pricing offset by weaker petchem margins. We see current valuations of 7.8x FY23E EPS and 6x EV/EBITDA (including investment value of Rs37/sh) as very attractive, with material improvement seen in prospects across business segments over the next 18-24 months. Reiterate BUY, with a revised TP of Rs195, 36% upside.

Financial and valuation summary

YE Mar (Rs mn)	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)	FY21	FY22E	FY23E
Revenue	1,73,839	1,20,869	43.8%	1,55,462	11.8%	5,67,302	6,84,142	6,72,348
EBITDA	24,113	6,226	287.3%	25,648	-6.0%	64,451	1,04,009	1,16,083
EBITDA margin(%)	13.9%	5.2%		16.5%		11.4%	15.2%	17.3%
EBIT	19,027	1,644	1057.7%	20,890	-8.9%	45,373	82,684	93,038
EBIT margin (%)	10.9%	1.4%		13.4%		8.0%	12.1%	13.8%
Adj. PAT	15,299	2,555	498.8%	19,077	-19.8%	48,902	73,637	81,024
Diluted EPS	3.4	0.6	498.8%	4.3	-19.8%	11.0	16.6	18.2
PER						13.0	8.6	7.8
EV/EBITDA						11.2	7.0	6.4
P/BV						1.4	1.2	1.1

Source: Company, Centrum Broking

Result Update

India I Oil & Gas

06 August, 2021

BUY

Price: Rs142

Target Price: Rs195

Forecast return: 37%

Institutional Research

Market Data

Bloomberg:	GAIL IN
52 week H/L:	170/81
Market cap:	Rs632.3bn
Shares Outstanding:	4440.4mn
Free float:	41.2%
Avg. daily vol. 3mth:	1,57,37,140

Source: Bloomberg

Changes in the report

Rating:	Unchanged
Target price:	Unchanged
EPS:	FY22E +1.3%, FY23E +3.7%

Source: Centrum Broking

Shareholding pattern

	Jun-21	Mar-21	Dec-20	Sep-20
Promoter	51.8	51.8	52.1	52.1
FII	17.0	15.6	15.6	15.1
DII	19.0	19.0	19.9	20.1
Public/other	12.2	13.5	12.4	12.7

Source: BSE

Centrum estimates vs Actual results

YE Mar (Rs mn)	Centrum Q1FY22	Actual Q1FY22	Variance (%)
Revenue	1,43,156	1,73,839	21.4
EBITDA	31,809	24,113	(24.2)
EBITDA margin	22%	14%	
PBT	28,999	20,537	(29.2)
Adj. PAT	21,700	15,299	(29.5)

Source: Bloomberg, Centrum Broking

Oil, Gas & Chemicals Team



Probal Sen

Analyst, Oil & Gas
+91 22 4215 9001
probal.sen@centrum.co.in

Thesis Snapshot

Estimate revision

YE Mar (Rs mn)	FY22E New	FY22E Old	% chg	FY23E New	FY23E Old	% chg
Revenue	6,84,142	6,85,573	-0.2%	6,72,348	6,66,146	0.9%
EBITDA	1,04,009	1,02,753	1.2%	1,16,083	1,12,253	3.4%
EBITDA margin	15.2%	15.0%		17.3%	16.9%	
Adj. PAT	73,637	72,697	1.3%	81,024	78,158	3.7%
Diluted EPS (Rs)	16.6	16.4	1.3%	18.2	17.6	3.7%

Source: Centrum Broking

GAIL versus NIFTY 50

	1m	6m	1 year
GAIL IN	(6.1)	11.5	53.2
NIFTY 50	3.0	9.2	45.5

Source: Bloomberg, NSE

Key assumptions

Y/E Mar	FY22E	FY23E
Brent (US\$/bbl)	65.0	65.0
INR/USD	74.5	75.0
Natural Gas Transmission		
Volumes (mmscmd)	110.0	118.8
Tariff (Rs/mcm)	1,575	1,575
LPG Transmission		
Volumes ('000 mt)	4,050	4,091
Tariff (Rs/mt)	1,619	1,635
Natural Gas Trading		
Volumes (mmscmd)	94.2	101.7
EBIT margin/mcm	500	500
Petrochemicals		
Sales Volumes ('000 mt)	709	789
Realisation (Rs/mt)	99,408	1,01,702
LPG and LHC		
Volumes ('000 mt)	1,165	1,190
Realisation (Rs/mt)	39,637	41,252


Source: Centrum Broking

Valuations


We value GAIL on EV/EBITDA multiples (FY22E) – using 5-7x EV/EBITDA multiples for the different business segments resulting in TP of Rs195/share. Reiterate BUY.

Valuations	Rs/share
Transmission (NG+LPG) @ 6.5x FY22e EV/E	79.4
NG Trading (6.5x FY22e EV/E)	26.8
Petchem 6x FY22e EV/E)	31.0
LPG +LHC (6.5x FY22e EV/E)	35.6
Other	(4.2)
Total EV	168.6
Net Debt	10.8
Core Business Equity Value	157.8
Listed Investments (@40% discount to CMP)	36.9
Target valuation	195
Upside (downside) from CMP (%)	36%

P/E mean and standard deviation



EV/EBITDA mean and standard deviation



Source: Bloomberg, Centrum Broking

Peer comparison

Company	Mkt Cap (Rs mn)	EPS CAGR (FY21-23E) (%)	PE (x)			P/Bv (x)			EV/EBITDA (x)			RoE (%)	RoCE (%)
			FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E		
GAIL	6,34,532	28.7%	13.0	8.6	7.8	1.4	1.2	1.1	10.5	6.6	6.0	15.0	13.9
PLNG	3,25,950	1.1%	11.1	11.3	10.8	2.8	2.6	2.3	5.7	5.6	5.0	22.5	22.5
GSPL	1,88,842	8.7%	21.4	20.1	18.1	2.5	2.3	2.0	13.3	12.7	11.4	12.5	12.2
GGL	5,31,445	24.4%	41.7	31.1	26.9	11.9	9.0	7.0	25.7	20.2	17.2	29.2	28.4
IGL	3,77,580	23.6%	37.5	27.3	24.6	6.4	5.5	4.8	24.8	18.4	15.6	20.8	20.7
MGL	1,16,205	26.4%	18.8	13.3	11.7	3.6	3.2	2.8	10.8	8.0	6.9	25.1	25.2

Source: Company, Centrum Broking

Exhibit 1: Quarterly Summary


Particulars (Rs bn)	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
Net Sales	1,83,106	1,82,259	1,77,673	1,77,531	1,20,869	1,36,427	1,54,543	1,55,462	1,73,839
Other Operating Income	-	1,860	-	-	-	-	-	-	-
Total Income	1,83,106	1,84,119	1,77,673	1,77,531	1,20,869	1,36,427	1,54,543	1,55,462	1,73,839
Accretion to Stocks in trade & work in progress	2,856	(584)	(3,952)	(4,307)	4,008	3,086	875	(2,532)	(1,016)
Raw Material Consumed	9,983	13,705	10,760	9,672	7,706	10,199	10,837	10,318	7,778
Purchase of Semi/finished goods/traded goods	1,32,476	1,36,220	1,33,632	1,33,144	88,318	95,369	1,07,504	1,07,799	1,27,209
Employee Expenses	4,197	4,268	3,472	3,256	3,978	4,083	4,041	3,361	4,257
Other Exp	11,005	13,023	13,038	11,013	10,633	10,310	12,090	10,869	11,497
Operating Profit (Core EBITDA)	22,590	17,487	20,724	24,754	6,226	13,381	19,195	25,648	24,113
Depreciation	4,057	4,398	4,890	5,016	4,583	4,843	4,895	4,758	5,086
EBIT	18,533	13,089	15,834	19,738	1,644	8,538	14,300	20,890	19,027
Interest	239	275	242	329	495	274	331	459	466
Other Revenue/Income	1,512	4,401	3,124	5,132	2,413	7,239	4,708	5,684	1,976
Other Excep. Items (restructuring, asset sales etc)	-	(1,860)	-	1,016	-	-	-	-	-
Profit Before Tax	19,805	15,355	18,716	25,557	3,562	15,503	18,677	26,116	20,537
Tax	6,930	4,713	6,210	(4,625)	1,007	3,107	3,804	7,039	5,238
<i>Tax rate (%)</i>	35.0%	30.7%	33.2%	-18.1%	28.3%	20.0%	20.4%	27.0%	25.5%
Profit After Tax	12,875	10,643	12,507	30,182	2,555	12,397	14,873	19,077	15,299
PAT attributable to Consolidated Group	12,875	10,643	12,507	30,182	2,555	12,397	14,873	19,077	15,299
Adjusted PAT for the group	12,875	11,889	12,507	22,049	2,555	12,397	14,873	19,077	15,299
Growth (%)									
<i>Net Sales</i>	5.9%	-4.3%	-10.2%	-5.4%	-34.0%	-25.1%	-13.0%	-12.4%	43.8%
<i>EBITDA</i>	-0.5%	-35.2%	-22.5%	47.0%	-72.4%	-23.5%	-7.4%	3.6%	287.3%
<i>Adj. PAT (stdnle)</i>	2.2%	-34.3%	-25.6%	64.4%	-80.2%	4.3%	18.9%	-13.5%	498.8%
Margin (%)									
<i>EBITDA</i>	12.3%	9.6%	11.7%	13.9%	5.2%	9.8%	12.4%	16.5%	13.9%
<i>EBIT</i>	10.1%	7.2%	8.9%	11.1%	1.4%	6.3%	9.3%	13.4%	10.9%
<i>PAT (reported bef minority interest)</i>	7.0%	5.8%	7.0%	17.0%	2.1%	9.1%	9.6%	12.3%	8.8%
Key Drivers									
Brent (US\$/bbl)	68.5	61.9	62.4	50.0	32.0	38.0	44.5	60.7	67.8
INR/USD	69.6	70.4	71.2	72.6	75.5	74.4	74.0	73.0	73.6
Natural Gas Transmission									
Volumes (mmscmd)	105.4	108.7	110.3	109.0	90.2	106.4	110.3	109.8	107.7
Tariff (Rs/mcm)	1,543	1,601	1,562	1,567	1,545	1,573	1,590	1,516	1,514
LPG Transmission									
Volumes ('000 mt)	827.0	999.0	1,043.0	1,040.0	963.0	1,058.0	1,088.0	1,054.0	1,023.0
Tariff (Rs/mt)	1,627	1,613	1,618	1,653	1,594	1,602	1,612	1,602	1,600
Natural Gas Trading									
Volumes (mmscmd)	96.6	94.7	96.0	97.8	81.2	88.6	95.6	91.4	96.0
EBIT margin/mcm	968.0	271.6	528.2	677.4	(738.5)	(451.4)	(84.7)	337.8	432.5
Petrochemicals									
Volumes ('000 mt)	136.0	217.0	211.0	174.0	183.0	224.0	231.0	234.0	138.0
Realisation (Rs/mt)	81,821	74,616	70,276	69,965	66,759	75,211	83,836	94,780	98,714
LPG and LHC									
Volumes ('000 mt)	296	329	337	302	265	297	319	257	250
Realisation (Rs/mt)	38,704	29,195	28,891	38,209	28,223	27,038	27,519	33,660	40,602

Source: Centrum Broking, Company Data


Exhibit 2: Key metrics

	Q4FY21	Q2FY22	Comments
Transmission volumes	The company revised its guidance with FY22E volumes now expected to be at 114-115mmscmd (FY21 volumes at 104mmscmd). The management is confident of healthy growth of 7-8% CAGR in the next three years and would see further increase in volumes once new Refinery/Petchem/Fertilizer plants/capacity are connected to the grid	GAIL has maintained its guidance of at least 8mmscmd growth in FY22 volumes for both transmission/trading driven by the commissioning of 4 new Fertilizer plants on the eastern gas grid	We have factored transmission volume for FY22/23E at 110/119mmscmd.
Trading volumes/margins	In FY22, 80% of volumes are tied up while 20% are open to gain spot price arbitrage. Outlook for the gas trading segment remains very robust for FY22E.	Majority of volumes have been sold/allocated for FY22/23E and thanks to favorable pricing economics, EBIT to be higher than FY19 levels (Rs28.6bn)	We have factored trading volumes of 94/102mmscmd and EBIT of Rs17/18bn for FY22/23
Capex guidance	The company has guided capex of Rs70/120bn for FY22/23. For the eastern gas grid, the company has outlay of Rs14,700 crore (actual Rs11,300 crore, capital grant Rs4,487cr). Total pipeline capex plan including JV at Rs37,000 crore for 7,500km of pipelines over the next 3-4 years. Even with expansion in pipeline network, management is targeting to achieve 75% utilization (from current 52%) in next 4-5 years.	Guidance maintained at the same levels .	No change in our assumptions of capex of Rs70bn for FY22E and Rs90bn for FY23E
Update on InVIT	Though the company did not disclose exact details, two pipelines have been proposed for InVIT program and the management is waiting for approvals before any disclosures.	No fresh update.	Company trying to unlock value though still at nascent stage.
Petchem outlook	Management remains positive on pricing outlook given the momentum in demand scenario.	Volumes suffered this quarter due to a planned shutdown but management remains confident of achieving full utilization of ~800ktpa for the full year.	Given pick-up in price realizations and volumes post Q1, we factor an EBIT of Rs14/18bn for FY22/23E.
Petchem production	The company has a capex plan to spend Rs100bn for 0.5mt additional capacity, which is expected to come online by FY24/25.	Guidance maintained.	We have factored petchem production to remain flat at 810/810kt for FY22/23E.
Renewables/Biogas	The company has an outlay of Rs30 crore for an initial CBG Plant having capacity of 5 tonnes per day at Ranchi. In FY22, it has planned another Rs50-60 crore capex for CBG plant. Apart from manufacturing, it will also be buying from manufacturers and earn marketing margins. GAIL will implement mixing/synchronizing with CGD to supply gas. In Renewables, it has a target of 1GW (solar/wind) in the next 3-4 years. It has capex plan of Rs4-6k crore for 1GW capacity.	No fresh update	Feedstock availability remains a key factor for CBG plant location selection. Renewables could be new growth driver for longer term.


Source: Company Data, Centrum Broking

Exhibit 3: Gas transmission volumes dip qoq...

Source: Company Data, Centrum Broking


Exhibit 4: ...while gas trading volumes improve

Source: Company Data, Centrum Broking

Exhibit 5: Transmission/Trading volumes


Source: Company Data, Centrum Broking

Seeing higher domestic gas supply, higher LNG and demand growth, we have factored in transmission and trading volume at 110/94mmscmd for FY22 and 119/102mmscmd for FY23 respectively.


Exhibit 6: ...reflecting in strong Gas transmission/trading EBIT in FY22/23E

Source: Company Data, Centrum Broking


We see steady earnings from Transmission and strong turnaround from Trading in FY22. Our transmission and Trading EBIT estimates at Rs36/17bn in FY22 and Rs 39/18bn in FY23 respectively resulting from volumes and higher differential in Asia vs US LNG prices.

Exhibit 7: Petchem production dips sharply


Source: Company Data, Centrum Broking

Exhibit 8: Dragging EBIT lower


Source: Company Data, Centrum Broking

Exhibit 9: We expect Petchem volumes to dip over FY22e, recover back to >100% utilisation by FY23e


Source: Company Data, Centrum Broking

Exhibit 10: ...strong realisations and margins to drive the EBIT growth in the petchem segment


Source: Company Data, Centrum Broking

Exhibit 11: LPG production and sales in Q4 declined


Source: Company Data, Centrum Broking

Exhibit 12: ...however LPG+LHC EBIT saw sharp growth


Source: Company Data, Centrum Broking

Exhibit 13: LPG + LHC volumes to also see a some recovery in FY22/23E

Source: Company Data, Centrum Broking

Exhibit 14: Financial metrics to show improvement with EBITDA/PAT to grow by 34/28% CAGR over FY21-23E

Source: Company Data, Centrum Broking

Exhibit 15: Return ratios to move start moving upwards in FY22/23E


Source: Company Data, Centrum Broking

Valuation – Reiterate BUY

Current valuations of 7.8x FY23E EPS/ 6x EV/EBITDA and 1.1x P/BV are not challenging, and we see increase in momentum in the next 12 months for GAIL, with strong earnings from Petchem.

We value GAIL using FY23E EV/EBITDA multiples of 5-6.5x across business segments, which delivers a target price of Rs195/share, 36% upside from CMP.

Exhibit 16: GAIL SoTP valuation summary

	FY23E	Multiple	EV
	(Rs mn)	(x)	(Rs mn)
GAIL segmental EBITDA			
Natural gas transmission	50,039	6.5	3,25,251
LPG transmission	4,222	6.5	27,445
NG and LPG transmission	54,261	6.5	3,52,695
NG Trading	18,306	6.5	1,18,989
Petchem	22,971	6.0	1,37,828
LPG and Liquid Hydrocarbons	24,292	6.5	1,57,897
Other unallocated	(3,747)	5.0	(18,735)
EBITDA	1,16,083	6.4	7,48,675
Net debt			48,119
Total Equity Value			7,00,556
# of shares			4,440
Equity value/ share			158
Listed Investments (30% discount to CMP)			37
Total Equity Value	195		
CMP			143
Upside (downside) %			36.2%

Source: Centrum Broking

P&L (Standalone)					
YE Mar (Rs mn)	FY19A	FY20A	FY21A	FY22E	FY23E
Revenues	7,48,983	7,20,570	5,67,302	6,84,142	6,72,348
Operating Expense	5,88,642	5,73,605	4,51,597	5,44,607	5,35,219
Employee cost	17,784	15,193	16,256	17,394	18,611
Others	49,287	46,218	34,997	18,131	2,435
EBITDA	93,271	85,554	64,451	1,04,009	1,16,083
Depreciation & Amortisation	15,502	18,360	19,079	21,325	23,045
EBIT	77,769	67,194	45,373	82,684	93,038
Interest expenses	1,385	1,085	1,559	3,035	3,827
Other income	15,448	14,168	20,045	18,757	19,067
PBT	90,848	79,434	63,858	98,406	1,08,278
Taxes	30,592	13,227	14,956	24,769	27,254
Effective tax rate (%)	33.7	16.7	23.4	25.2	25.2
PAT	60,257	66,206	48,902	73,637	81,024
Minority/Associates	0	0	0	0	0
Recurring PAT	60,916	59,320	48,902	73,637	81,024
Extraordinary items	(659)	6,887	0	0	0
Reported PAT	60,257	66,206	48,902	73,637	81,024
Ratios					
YE Mar	FY19A	FY20A	FY21A	FY22E	FY23E
Growth (%)					
Revenue	39.6	(3.8)	(21.3)	20.6	(1.7)
EBITDA	22.2	(8.3)	(24.7)	61.4	11.6
Adj. EPS	32.4	(2.6)	(17.6)	50.6	10.0
Margins (%)					
Gross	21.4	20.4	20.4	20.4	20.4
EBITDA	12.5	11.9	11.4	15.2	17.3
EBIT	10.4	9.3	8.0	12.1	13.8
Adjusted PAT	8.1	8.2	8.6	10.8	12.1
Returns (%)					
ROE	14.4	13.5	10.8	15.0	15.0
ROCE	14.1	14.4	9.9	13.9	13.9
ROIC	10.4	10.1	5.9	9.3	9.4
Turnover (days)					
Gross block turnover ratio (x)	2.0	1.7	1.2	1.4	1.3
Debtors	22	27	32	26	29
Inventory	13	17	22	19	21
Creditors	24	26	34	31	33
Net working capital	17	29	27	24	22
Solvency (x)					
Net debt-equity	0.0	0.1	0.1	0.1	0.1
Interest coverage ratio	67.3	78.9	41.3	34.3	30.3
Net debt/EBITDA	0.0	0.5	0.7	0.5	0.6
Per share (Rs)					
Adjusted EPS	13.7	13.4	11.0	16.6	18.2
BVPS	99.3	99.0	105.0	115.8	127.6
CEPS	17.2	17.5	15.3	21.4	23.4
DPS	3.9	6.5	5.0	5.8	6.4
Dividend payout (%)	28.8	43.6	45.4	35.0	35.0
Valuation (x)					
P/E	10.4	10.7	13.0	8.6	7.8
P/BV	1.4	1.4	1.4	1.2	1.1
EV/EBITDA	6.8	8.0	10.5	6.6	6.0
Dividend yield (%)	2.7	4.5	3.5	4.1	4.5

Source: Company, Centrum Broking

Balance sheet					
YE Mar (Rs mn)	FY19A	FY20A	FY21A	FY22E	FY23E
Equity share capital	22,551	45,101	44,404	44,404	44,404
Reserves & surplus	4,18,379	3,94,610	4,21,708	4,69,572	5,22,238
Shareholders fund	4,40,930	4,39,711	4,66,112	5,13,976	5,66,642
Minority Interest	0	0	0	0	0
Total debt	10,011	54,118	55,656	57,177	72,023
Non Current Liabilities	34,384	44,860	56,056	57,738	59,470
Def tax liab. (net)	59,477	44,972	45,022	44,396	43,744
Total liabilities	5,44,801	5,83,661	6,22,846	6,73,287	7,41,879
Gross block	3,69,602	4,13,331	4,60,939	4,95,939	5,35,939
Less: acc. Depreciation	(58,741)	(76,881)	(95,960)	(1,17,285)	(1,40,330)
Net block	3,10,861	3,36,450	3,64,979	3,78,654	3,95,609
Capital WIP	92,025	1,05,819	1,19,034	1,54,034	2,09,034
Net fixed assets	4,02,886	4,42,269	4,84,014	5,32,688	6,04,643
Non Current Assets	0	0	0	0	0
Investments	1,06,204	84,013	96,273	96,273	96,273
Inventories	23,219	29,601	26,038	31,401	30,860
Sundry debtors	50,743	55,759	44,858	54,097	53,164
Cash & Cash Equivalents	12,147	8,039	13,618	9,058	5,016
Loans & advances	48,587	65,655	68,304	68,304	68,304
Other current assets	0	0	0	0	0
Trade payables	39,612	41,284	43,264	49,913	47,859
Other current liab.	45,120	47,544	53,395	53,609	53,725
Provisions	14,253	12,847	13,600	15,013	14,797
Net current assets	35,711	57,379	42,559	44,325	40,963
Total assets	5,44,801	5,83,661	6,22,846	6,73,287	7,41,879
Cashflow					
YE Mar (Rs mn)	FY19A	FY20A	FY21A	FY22E	FY23E
Profit Before Tax	90,848	79,434	63,858	98,406	1,08,278
Depreciation & Amortisation	15,502	18,360	19,079	21,325	23,045
Net Interest	(3,066)	(2,027)	(6,305)	(2,020)	(1,228)
Net Change – WC	(3,282)	3,073	22,210	(6,490)	(849)
Direct taxes	(20,764)	(19,555)	(12,754)	(25,395)	(27,904)
Net cash from operations	78,763	68,881	80,639	78,327	93,842
Capital expenditure	(72,022)	(54,345)	(49,767)	(70,000)	(95,000)
Acquisitions, net	0	0	0	0	0
Investments	0	0	0	0	0
Others	17,656	(13,944)	11,158	12,719	12,723
Net cash from investing	(54,366)	(68,289)	(38,609)	(57,281)	(82,277)
FCF	6,741	14,536	30,872	8,327	(1,158)
Issue of share capital	0	0	(12,810)	0	0
Increase/(decrease) in debt	(11,348)	45,196	4,564	1,521	14,846
Dividend paid	(20,886)	(39,421)	(22,371)	(25,773)	(28,358)
Interest paid	(1,417)	(1,132)	(3,199)	(3,035)	(3,827)
Others	(3,894)	(9,344)	(1,575)	1,682	1,732
Net cash from financing	(37,544)	(4,700)	(35,391)	(25,605)	(15,607)
Net change in Cash	(13,147)	(4,109)	6,639	(4,560)	(4,042)

Source: Company, Centrum Broking

Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company. Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum. Centrum or its affiliates do not make a market in the security of the company for which this report or any report was written. Further, Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the foregoing limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by him, Mr. Probal Sen, research analyst and and/or any of their family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by them, they are not received any compensation from the above companies in the preceding twelve months. They do not hold any shares by them or through their relatives or in case if holds the shares then will not to do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

Ratings definitions

Our ratings denote the following 12-month forecast returns:

Buy – The stock is expected to return above 15%.

Add – The stock is expected to return 5-15%.

Reduce – The stock is expected to deliver -5-+5% returns.

Sell – The stock is expected to deliver <-5% returns.

GAIL



Source: Bloomberg

Disclosure of Interest Statement

1 Business activities of Centrum Broking Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager.

2 Details of Disciplinary History of CBL CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.

3 Registration status of CBL: CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)

GAIL

4 Whether Research analyst's or relatives' have any financial interest in the subject company and nature of such financial interest No

5 Whether Research analyst or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document. No

6 Whether the research analyst or his relatives has any other material conflict of interest No

7 Whether research analyst has received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received No

8 Whether the Research Analyst has received any compensation or any other benefits from the subject company or third party in connection with the research report No

9 Whether Research Analysts has served as an officer, director or employee of the subject company No

10 Whether the Research Analyst has been engaged in market making activity of the subject company. No

11 Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past twelve months; No

12 Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months; No

13 Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months; No

Member (NSE and BSE). Member MSEI (Inactive)

Single SEBI Regn No.: INZ000205331

Depository Participant (DP)

CDSL DP ID: 120 – 12200

SEBI REGD NO.: CDSL: IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Research Analyst

SEBI Registration No. INH000001469

Mutual Fund Distributor

AMFI REGN No. ARN- 147569

Website: www.centrum.co.in

Investor Grievance Email ID: investor.grievances@centrum.co.in

Compliance Officer Details:

Ashok D Kadambi

(022) 4215 9937; Email ID: compliance@centrum.co.in

Centrum Broking Ltd. (CIN :U67120MH1994PLC078125)**Registered Office Address**

Bombay Mutual Building,
2nd Floor, Dr. D. N. Road,
Fort, Mumbai - 400 001

Corporate Office & Correspondence Address

Centrum House
6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E), Mumbai
400 098.
Tel: (022) 4215 9000 Fax: +91 22 4215 9344